This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Familial hypokalemic periodic paralysisFamilial Hypokalemic Periodic Paralysis (HypoPP)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: G72.3 | Special Copayment Reduction: V258 (5 years)
B. SynonymsPeriodic paralysis (familial hypokalemic), HypoPP, Familial Periodic Paralysis type 1 (CACNA1S), type 2 (SCN4A)
C. Adult onsetFirst onset in adulthood likely — onset in the teens to 20s is typical; the first attack sometimes appears after the 20s
1. HistoryHistory of research from Westphal's first description in the late 19th century to identification of the CACNA1S and SCN4A genes
2. CausesCACNA1S (HypoPP1, ~70%), SCN4A (HypoPP2, ~10%) mutations; abnormalities of the channel voltage-sensing domain
3. GeneticsAutosomal dominant; CACNA1S at 1q32, SCN4A at 17q23; penetrance 90% in males, 50% in females
4. EpidemiologyPrevalence about 1 per 100,000; severe presentation more common in males; periodic paralysis with hyperthyroidism is common in Asian males
5. PathophysiologyR→H/G substitution in the voltage-sensing domain → nonselective cation leak channel (gating pore current) → depolarization → muscle fiber inexcitability
6. SymptomsEpisodic muscle weakness (hours to days), hypokalemia; triggered after carbohydrates or strenuous exercise; interictal myopathy
7. SignsLoss of deep tendon reflexes and muscle weakness during attacks; electrical silence on electromyography; interictal fixed muscle weakness
8. ScreeningSerum potassium measurement during attacks; electrocardiogram (U waves, QT prolongation); taking a family history
9. DiagnosisGenetic testing (CACNA1S, SCN4A); provocative tests (carbohydrate loading, insulin-glucose, exercise provocation); long exercise EMG test
10. TreatmentAcute phase: oral/intravenous potassium supplementation; prevention: acetazolamide (preferred for CACNA1S), dichlorphenamide; dietary modification
11. PrognosisWith long-term recurrent attacks, interictal myopathy (fixed muscle weakness) progresses; quality of life can be maintained with appropriate preventive treatment
12. PreventionAvoid high-carbohydrate diets, rest adequately after strenuous exercise, minimize cold exposure; genetic counseling
13. ReferencesVenance SL et al. (2006) and 9 other key papers

1. History

The clinical description of hypokalemic periodic paralysis began in 1885, when Carl Friedrich Otto Westphal first reported the association between episodic muscle paralysis and changes in serum electrolytes. This case showed a pattern of sudden loss of limb strength after exercise or excessive carbohydrate intake with spontaneous recovery within hours, and there were similar patients in the family. Subsequently, as several researchers published similar cases, "periodic paralysis" was established as an independent clinical entity. In the 1930s, a marked fall in serum potassium during attacks was consistently confirmed, making it clear that hypokalemia is central to the pathophysiology.

The molecular genetic cause was revealed in 1994 when Fontaine and colleagues identified variants of the CACNA1S gene (then CACNL1A3) in type 1 (HypoPP1). CACNA1S encodes the α1 subunit of the voltage-dependent L-type calcium channel of the skeletal muscle transverse tubule (T-tubule). Later, in 2001, Jurkat-Rott and colleagues discovered variants of the voltage-dependent sodium channel gene SCN4A in type 2 (HypoPP2). In 2008, Sokolov and colleagues and Struyk and colleagues elucidated the pathogenic mechanism by which these variants cause muscle cell depolarization by generating a "gating pore current (omega current)" through substitution of arginine residues located in the S4 helix of the voltage-sensing domain (VSD). With this, familial hypokalemic periodic paralysis became established as one of the representative examples of channelopathy. Subsequently, the efficacy of acetazolamide and differences in response by genotype were systematically studied, and the current standard treatment guidelines were established.

2. Causes

The cause of familial hypokalemic periodic paralysis is pathogenic variants in genes encoding skeletal muscle ion channel proteins. To date, two major causative genes have been identified.

CACNA1S (HypoPP type 1, ~70%): Located on the long arm of chromosome 1 (1q32), it encodes the α1S subunit of the transverse tubule voltage-dependent L-type calcium channel (DHPR, dihydropyridine receptor). The most common pathogenic variants are p.Arg528His, p.Arg1239His and p.Arg1239Cys, all of which substitute arginine residues of the S4 helix of the voltage-sensing domain (domain II or IV). In patients with CACNA1S variants, provocation of attacks by carbohydrate loading or insulin administration is typical, and the response to acetazolamide is relatively better than in HypoPP2 (response rate about 56%).

SCN4A (HypoPP type 2, ~10%): Located on the long arm of chromosome 17 (17q23), it encodes the α subunit of the skeletal muscle voltage-dependent sodium channel Nav1.4. Frequent pathogenic variants include p.Arg672His, p.Arg672Gly, p.Arg672Ser and p.Arg1132His. In HypoPP2, acetazolamide can actually increase attack frequency with some variants (Arg672Gly, Arg672Ser), so caution is needed. The response rate is only about 16%. In patients with SCN4A variants, clinical features overlapping with other channelopathies, such as hyperkalemic periodic paralysis and paramyotonia congenita, may appear.

Cases in which no variant is found in either gene ("genotype-negative HypoPP") account for about 20%, and in such cases variants in other genes such as KCNJ2 (Andersen-Tawil syndrome), KCNJ5 and ATP1A2 or in undiscovered genes should be considered. Hyperthyroidism-related hypokalemic periodic paralysis (thyrotoxic periodic paralysis, TPP) has a separate pathophysiology (including KCNJ18 variants) and is particularly frequent in Asian males.

3. Genetics

Familial hypokalemic periodic paralysis follows an autosomal dominant (AD) mode of inheritance. A single pathogenic variant is sufficient to cause the disease, and it is transmitted to 50% of the children of variant carriers. However, there is a marked sex difference in penetrance: about 90% of male variant carriers experience clinical symptoms, whereas only about 50% of females develop the disease, and their symptoms tend to be mild. This sex difference in penetrance has been explained by the possibility that estrogen acts protectively in regulating ion channel function in muscle cells and by sex differences in body composition and metabolic rate, but the molecular mechanism has not been fully elucidated.

De novo variants have also been reported, so the diagnosis should not be excluded on the basis of no family history. For both CACNA1S and SCN4A, point mutations (missense) are the main variant type, and recurrent variants (hotspot mutations) at specific arginine residues of the S4 helix of the voltage-sensing domain (Arg528, Arg1239, etc.) account for the majority. Regarding genotype-phenotype correlation, age of onset, attack frequency, degree of hypokalemia, acetazolamide response and others are related to the location of the variant. Genetic testing is performed by high-resolution melting analysis, Sanger sequencing or channelopathy gene panel NGS, and if no confirmatory variant is found, WES or RNA analysis is considered.

4. General epidemiology

The prevalence of familial hypokalemic periodic paralysis is estimated at about 1 per 100,000 in the general population, and it is the most common type of familial periodic paralysis. Prevalence and symptom severity are higher in males. Onset is typically in the teens to 20s, and in some the first attack occurs in childhood. In females, onset is often later and symptoms milder, which can delay diagnosis.

Geographic and ethnic differences have also been reported. HypoPP1 (CACNA1S) variants are relatively frequent in people of European descent, and HypoPP2 (SCN4A) is also reported at considerable frequency in people of Asian descent. Hyperthyroidism-related hypokalemic periodic paralysis (thyrotoxic periodic paralysis, TPP) is particularly common in Asian males and is known to occur in 1–2% of patients with Graves' disease. TPP involves separate gene variants such as KCNJ18 and is distinguished from familial HypoPP by the disappearance of attacks after normalization of thyroid function.

Attack frequency varies greatly between individuals, ranging from a few attacks a year to attacks almost every day. After the 40s–50s, attack frequency tends to decrease, but at the same time fixed muscle weakness due to interictal myopathy begins to progress.

5. Pathophysiology

The core pathophysiology of familial hypokalemic periodic paralysis is paradoxical depolarization due to ion channel dysfunction of the muscle cell membrane. In normal muscle fibers, the cell membrane normally hyperpolarizes when serum potassium falls, but in patients with HypoPP, depolarization occurs instead, producing an inexcitable state in which action potentials cannot be generated.

Gating pore current (omega current): In the S4 helices of the voltage-sensing domains (domains II, III, IV) of CACNA1S and SCN4A, positively charged arginine (Arg) residues are normally arranged at regular intervals. When these residues are replaced by histidine (His), glycine (Gly) or serine (Ser), a nonselective cation-permeable pathway (gating pore) forms within the voltage-sensing domain. Sodium ions continuously enter the cell through this pathway ("gating pore current" or "ω current"), progressively depolarizing the muscle cell membrane potential.

Role of hypokalemia: Hypokalemia shifts the membrane potential further in the depolarizing direction and deepens sodium channel inactivation. Carbohydrate loading, insulin administration and high-intensity exercise promote intracellular potassium uptake, transiently lowering serum potassium further, which accelerates muscle fiber depolarization and inexcitability and triggers attacks.

Mechanism of interictal myopathy: During repeated attacks, intracellular sodium and calcium overload and vacuolation of muscle cells accumulate, and structural damage to muscle cells is known to become permanent. Tubular aggregates, lysosomal autophagic vacuoles and muscle fiber necrosis observed on muscle biopsy reflect this chronic damage.

6. Symptoms

The main symptoms of hypokalemic periodic paralysis are episodic muscle weakness and the accompanying hypokalemia.

Episodic muscle weakness: A typical attack begins with marked loss of limb strength after waking early in the morning. Attack intensity ranges from transient weakness to complete quadriplegia. Proximal muscles (pelvic and proximal lower limb muscles, shoulder muscles) are mainly involved first, and in severe cases respiratory and swallowing muscles are also involved. Attacks last from several hours to at most several days (24–72 hours) and improve quickly with spontaneous recovery or potassium supplementation.

Triggers: Excessive intake of carbohydrates (especially sugars), rest immediately after high-intensity exercise, stress, cold exposure, menstruation, alcohol and insulin administration are typical triggers. The association between carbohydrate intake and attacks is explained by the rapid intracellular shift of serum potassium due to postprandial insulin secretion.

Interictal symptoms: In periods without attacks, there are generally no or mild symptoms. However, as the disease progresses over decades, "interictal myopathy" appears, in which fixed proximal weakness slowly progresses even as the number of attacks decreases. This is commonly recognized after the 30s–40s and presents as difficulty climbing stairs, difficulty rising from the floor and so on.

Cardiac symptoms: When hypokalemia becomes severe during an attack, ECG abnormalities (appearance of U waves, T-wave flattening, QT prolongation, rarely ventricular arrhythmias) occur. In severe hypokalemia (K⁺ <2.5 mEq/L) there is a risk of fatal arrhythmia, so ECG monitoring is needed.

7. Signs

Physical examination findings differ between the attack phase and the interictal phase.

Findings during attacks: Limb weakness appears symmetrically and ranges from MRC grade 0 to 3. When respiratory muscle weakness is present, increased respiratory rate and paradoxical chest movement are observed. Deep tendon reflexes (DTR) are reduced or absent during attacks. Sensation is preserved (this is important for differentiation from motor nerve or neuromuscular junction disorders). Myotonia is in principle absent in HypoPP, but in some cases with SCN4A variants mild myotonia may be present before and after attacks.

Interictal findings: Early in the disease, examination findings are normal. After long-term recurrent attacks, proximal muscle weakness (especially hip flexion, knee extension) is observed as fixed weakness, and calf muscle atrophy may appear. Myocardial involvement is generally absent.

ECG findings: When serum potassium falls below 3 mEq/L during an attack, U waves (reflecting atrioventricular node repolarization), T-wave flattening or inversion and PR interval prolongation are observed. When potassium falls to 2.5 mEq/L or below, ST depression, sinus tachycardia and rarely ventricular tachycardia may occur.

EMG findings: During attacks, reduced or absent spontaneous potentials (electrical silence) and reduced motor unit potential amplitude are characteristic. In the interictal phase, when interictal myopathy has progressed, myopathic changes (short polyphasic motor unit potentials) are observed. The long exercise test is useful for diagnosis and shows a decrease in the compound muscle action potential (CMAP) after exercise of 40% or more from baseline.

8. Screening

When periodic paralysis is clinically suspected, the following initial screening tests are performed.

Serum electrolyte measurement during attacks: Serum potassium is measured immediately when an attack occurs. In hypokalemic periodic paralysis, K⁺ typically falls to 2.5–3.5 mEq/L (in some, to 2.0 mEq/L or below). At the same time, serum sodium, magnesium, phosphorus and thyroid function tests are performed to exclude secondary causes (hyperthyroidism, aldosteronism, Bartter syndrome, illicit drug use).

Electrocardiogram (ECG): Assesses the cardiac effects of hypokalemia during attacks. U waves, T-wave abnormalities and QTc prolongation suggest the need for immediate potassium supplementation.

CK measurement: There may be a mild CK elevation after an attack. Because it is mostly within the normal range in the interictal phase, it is not specific for diagnosis, but it is used as a reference for differentiation from other myopathies.

Checking family history: A family history of similar episodic muscle weakness, hypokalemia and periodic paralysis is systematically taken. If there is a family history, targeted genetic testing based on the causative gene test results of the confirmed family member is performed first.

9. Diagnosis

Genetic testing: When hypokalemic periodic paralysis is clinically suspected, channelopathy gene panel NGS including CACNA1S and SCN4A is the most direct way to confirm the diagnosis. Sanger sequencing of these genes is also possible. When a variant is identified, the diagnosis is confirmed, and the functional significance of the variant found (pathogenic/benign/VUS) is assessed according to ACMG criteria.

Provocative test: When no clear variant is found on genetic testing or an immediate diagnosis is needed, a provocative test is performed. However, it must be performed in a monitored setting (ECG, oxygen saturation, frequent serum potassium measurement) under the supervision of specialist medical staff. ① Carbohydrate-insulin provocative test: in the fasting state, oral glucose 2 g/kg (maximum 100 g) followed by insulin (0.1 U/kg), or intravenous insulin alone. ② Exercise provocative test: rest after 30 minutes of bicycle ergometer exercise. It is judged positive if muscle weakness is reproduced as serum K⁺ falls to <3.0 mEq/L.

Long exercise EMG test: The change in CMAP amplitude before and after a stepwise standardized exercise (rest after 5 minutes of maximal contraction) is measured. A decrease in CMAP of 40% or more from baseline within 20–40 minutes after exercise suggests a channelopathy. It is safer than provocative testing and can be performed in the outpatient setting.

Muscle biopsy: Not essential for all patients, but when interictal myopathy is present, muscle biopsy may show tubular aggregates, vacuolar changes, fatty infiltration and so on. It is performed selectively to differentiate secondary causes or exclude coexisting muscle disease.

10. Treatment

Treatment of acute attacks: Oral potassium supplementation during an attack is the first-line treatment. KCl solution (oral) 40–60 mEq is given as a starting dose, with additional doses according to serum K⁺ and the course of symptoms. When oral administration is not possible or serum K⁺ is severely low at below 2.5 mEq/L, intravenous KCl supplementation (caution: in normal saline, not glucose solution) is given. Intravenous KCl is given at no more than 20 mEq/hour under ECG monitoring. Carbohydrate intake is stopped immediately. There are reports that mannitol shortens attack duration through osmotic diuresis.

Preventive treatment of attacks: ① Acetazolamide (carbonic anhydrase inhibitor): the first-line preventive agent in HypoPP1 (CACNA1S). It is given at 125–1000 mg/day in divided doses, suppressing potassium excretion through acidification of the urine and indirectly modulating calcium channel activity. It reduces attack frequency in about 56% of patients with CACNA1S variants. ② Dichlorphenamide: another FDA-approved carbonic anhydrase inhibitor with a mechanism similar to acetazolamide, but effective in some nonresponders. ③ Potassium-sparing diuretics: the combination of spironolactone (25 mg twice daily) and amiloride (5–10 mg/day) is an alternative in patients for whom acetazolamide is ineffective or not tolerated. ④ Carbohydrate-restricted diet, low-sodium diet: minimizing triggers is an important nonpharmacologic preventive strategy. In HypoPP2 (SCN4A, Arg672Gly/Ser variants), acetazolamide is contraindicated.

Management of interictal myopathy: When fixed muscle weakness has progressed, preventive treatment of attacks is optimized, and rehabilitative physical therapy is used to maintain muscle strength.

11. Prognosis

In familial hypokalemic periodic paralysis, the attacks themselves rarely threaten life, but interictal myopathy over the long-term course greatly affects patients' quality of life and functional independence.

Attack frequency generally peaks in childhood and adolescence and decreases after the 40s. At the same time, however, fixed muscle weakness slowly progresses from this age group. Permanent proximal lower limb weakness is reported to occur in about 30–60% of patients, reflecting the accumulation of structural damage to muscle fibers from repeated attacks. Only a minority progress to the stage of needing a walking aid or wheelchair, but the decline in daily functioning is considerable.

There is clinical evidence that markedly reducing attack frequency with appropriate preventive treatment (acetazolamide, etc.) can also slow the progression of interictal myopathy. Therefore, early diagnosis and adherence to long-term preventive treatment are the most important prognostic factors. Arrhythmias due to hypokalemia during severe attacks are rare but can have fatal consequences, so ECG monitoring and prompt potassium supplementation during attacks are important. During pregnancy, attack frequency may change, and individual risk assessment and enhanced monitoring are needed.

12. Prevention

Prevention of hypokalemic periodic paralysis consists of avoiding triggers, pharmacologic prevention and genetic counseling.

Avoiding triggers: ① Refrain from high-carbohydrate, high-sugar diets (in particular, avoid concentrated carbohydrate intake before meals in those with a history of attacks). ② Avoid abrupt rest immediately after strenuous exercise, and continue light activity after exercise to soften a sharp fall in serum potassium. ③ Minimize cold exposure (especially outdoor work in low temperatures, exposure to cold water). ④ Use caution when prescribing drugs that promote insulin secretion (sulfonylureas, glinides, etc.), steroids and diuretics (thiazides, loop diuretics). ⑤ Manage stress and sleep deprivation.

Dietary guidelines: Regular intake of potassium-rich foods (bananas, avocados, tomatoes, potatoes) is recommended. Because excessive sodium intake promotes potassium excretion, a low-sodium diet is recommended. There are small reports that a ketogenic diet (low-carbohydrate, high-fat diet) may help reduce attacks.

Genetic counseling and family screening: First-degree relatives of confirmed patients are screened by CK measurement and CACNA1S/SCN4A gene testing. Asymptomatic carriers should also be educated about triggers and how to respond in emergencies. When planning pregnancy, counseling on preimplantation genetic diagnosis (PGT) is provided.

13. References

  1. Venance SL, Cannon SC, Fialho D, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain. 2006;129(Pt 1):8–17. PMID: 16195244
  2. Jurkat-Rott K, Lehmann-Horn F. Genotype-phenotype correlation and therapeutic rationale in hyperkalemic periodic paralysis. Neurotherapeutics. 2007;4(2):216–224. PMID: 17395131
  3. Sternberg D, Maisonobe T, Jurkat-Rott K, et al. Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain. 2001;124(Pt 6):1091–1099. PMID: 11353723
  4. Matthews E, Labrum R, Sweeney MG, et al. Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology. 2009;72(18):1544–1547. PMID: 19414723
  5. Cannon SC. Channelopathies of skeletal muscle excitability. Compr Physiol. 2015;5(2):761–790. PMID: 25880512
  6. Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2018;57(4):522–530. PMID: 29350763
  7. Tricarico D, Camerino DC. Pharmacological advances in the treatment of skeletal muscle channelopathies. Curr Opin Pharmacol. 2011;11(3):299–305. PMID: 21515095
  8. Elbaz A, Vale-Santos J, Jurkat-Rott K, et al. Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3). Neurology. 1995;45(3 Pt 1):603–604. PMID: 7897391
  9. Hanna MG, Stewart J, Schapira AH, Wood NW, Morgan-Hughes JA, Murray NM. Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene. J Neurol Neurosurg Psychiatry. 1998;65(2):248–250. PMID: 9703177
  10. Fontaine B, Vale-Santos J, Jurkat-Rott K, et al. Mapping of the hypokalaemic periodic paralysis (HypoPP) locus to chromosome 1q31-32 in three European families. Nat Genet. 1994;6(3):267–272. PMID: 8012386